Trulieve (TRLV): A 228% Tax Rate, the NYSE, and the First Profit in Years

RoboSystems Cannabis Coverage v2 · Filing base: FY2025 10-K (filed Feb 26, 2026) + Q1 FY2026 10-Q (filed May 7, 2026) · Priced June 22, 2026 ($9.13) · All filing figures from the RoboSystems SEC graph (CIK 0001754195 / legacy ticker TCNNF); market, uplisting and policy figures from attributed web sources. Not investment advice. No price targets.

1. The Hook

In fiscal 2025 Trulieve did $1.18 billion in revenue at a 60% gross margin and generated a record $273 million of operating cash flow — and still reported a $116 million GAAP net loss. Not because the business lost money. Its pretax income was positive $91 million. It lost money on paper because the IRS taxed it at an effective rate of 228% — $208 million of income tax on $91 million of pretax profit — under Section 280E, the tax code written to stop drug traffickers from deducting business expenses.

Stretch that out and it gets more absurd. Across 2021–2025, Trulieve paid or accrued $866 million in income taxes on roughly $7 million of cumulative pretax income. That is the entire cannabis investment thesis in one company: a profitable, cash-generative, market-leading operator whose only reason for showing a loss is a tax code that a partial federal rescheduling just started to dismantle. On June 10, 2026, Trulieve became the first U.S. plant-touching cannabis company ever to list on a major American exchange (NYSE: TRLV). Nobody on Wall Street has covered this stock for a decade. That's exactly why it's worth covering now.

2. Company Snapshot

Trulieve is the largest U.S. multi-state cannabis operator by retail footprint — 234 dispensaries and over 4 million square feet of cultivation and processing across its Southeast, Northeast and Southwest hubs, anchored in Florida, Pennsylvania and Arizona. It is unusually concentrated and unusually medical: Florida alone is ~162 of its dispensaries, 85% of its stores serve medical-only patients, and 94% of revenue is retail. That concentration is the whole story — it's why Trulieve runs best-in-class margins, why it could legally ring-fence a medical-only entity to clear the NYSE, and why it captures more 280E relief, sooner, than any peer. The numbers here come from the FY2025 10-K and the Q1 FY2026 10-Q; RoboSystems still keys the company by its legacy OTC ticker TCNNF (CIK 0001754195), not the new TRLV symbol.

3. The Financial Story

The top line is flat; that's not the point. Revenue was $1,181 million in FY2025 versus $1,186 million in FY2024 — down 0.4%, with Q1 FY2026 at $287 million, down ~3.7% year over year. Florida price compression and a softer consumer are real, and management guided 2026 revenue down low-to-mid single digits sequentially. But unit volume and traffic each rose ~5% in 2025; this is a price story, not a demand story. The interesting line isn't revenue — it's everything below it.

Margins and cash flow are genuinely best-in-class. Gross margin held at 60.2% in FY2025 ($711 million of gross profit) and 59% in Q1 FY2026 — the highest of any Tier 1 MSO, a product of vertical integration, scale, and disciplined promotion. Operating income was $143 million. Adjusted EBITDA was a record $427 million (36% margin). Operating cash flow hit a record $273 million and free cash flow a record $229 million — a ~12% free-cash-flow yield on today's ~$1.9 billion market cap. Management redeemed $368 million of 8% notes due 2026 in December and refinanced into 10.5% notes due 2030, ending the year with $256 million cash against ~$232 million of funded debt. This is not a distressed balance sheet; among Tier 1 MSOs only Green Thumb's is cleaner.

So where did the loss come from? 280E, and almost nothing else. Section 280E bars a Schedule I "trafficker" from deducting any expense except cost of goods sold. The result is a tax bill calculated on gross profit, not net profit — so Trulieve owes tax even in years it loses money on the books. FY2025: $91 million pretax, $208 million of income tax, a 228% effective rate, a $116 million net loss. FY2024 was worse on a rate basis — $43 million pretax, $198 million of tax, a 463% rate. The five-year picture ($866 million of tax on ~$7 million of cumulative pretax income) shows 280E isn't a headwind, it's the entire weather system.

The boom-bust arc is in the rear-view, but visible. Trulieve earned $18 million net in 2021, then bled — $(246)M in 2022 and $(527)M in 2023, the latter a goodwill-and-intangibles impairment year as the 2021 acquisition spree (Harvest Health, $2.1B of deals) was written down. Revenue peaked at $1.22 billion in 2022 and has drifted sideways since. What's left on the balance sheet is $484 million of goodwill and $798 million of intangibles — together ~47% of the $2.7 billion asset base — so impairment risk isn't fully behind it if Florida stays soft. But the operating reset is done: costs are out (SG&A fell from 43% to 38% of revenue), and the company throws off cash. The only thing standing between Trulieve and clean GAAP profitability is the tax line.

4. Catalyst Scenarios — How the Math Changes

The 280E switch is already flipping — you can see it in Q1. A partial, medical-only Schedule III order took effect April 28, 2026, and Treasury's transition rule effectively applies relief from January 1, 2026 for calendar-year filers' medical activity. Trulieve's Q1 FY2026 is the first read on it: the effective tax rate fell from 258% in Q1 2025 to 87% in Q1 2026, and the company posted positive net income of $2.4 million — its first profitable GAAP quarter in years — on lower revenue. The catalyst isn't hypothetical here; it's in the filing.

The full pro forma (apply a normal 25% rate to actual pretax income):

Remove 280E only. FY2025 pretax of $91 million taxed at 25% is ~$23 million, not $208 million. That turns a $116 million loss into ~$69 million of net income — a $185 million swing, the annual 280E penalty. Adjusted EPS ~$0.33, an implied ~28x P/E at $9.13.
Normalize the one-time Florida ballot spend too. Trulieve burned $66 million on the failed 2026 adult-use campaign — a cost that cannot recur (Florida adult-use is legally dead until 2028). Add it back and 280E-relieved earnings rise to ~$118 million, ~$0.57 EPS, an implied ~16x at today's price. That's the "normal business" earnings number.

Why Trulieve captures more relief than anyone — now. Relief currently applies only to medical income; adult-use stays Schedule I and keeps paying 280E. Trulieve is ~medical and Florida-dominant, and it just deconsolidated its mixed-use (medical + adult-use) operations into a separate vehicle, Harvest Enterprises LLC (outside investor Whitley Holdings took a 10% economic stake for $14.8 million and two of three board seats; Trulieve keeps 90% economics via non-voting exchangeable units). The listed entity, TRLV, is now a DEA-registered, medical-only operator — the cleanest 280E-relief profile in the sector, and the exact structure that cleared the NYSE.

But hold the back-tax overhang separate from the earnings. Going-forward relief improves the income statement; it does not erase the bill Trulieve already ran up by betting early that 280E never validly applied. The company filed amended returns claiming ~$143 million of refunds and received ~$114 million — and the IRS is fighting that theory hard (it sued TerrAscend in May 2026 to claw back an $8.3 million refund). Trulieve's uncertain-tax-position reserve was $668 million at year-end 2025 ($630 million tied to 280E) and grew to ~$696 million by Q1 FY2026 — still accruing ~$28 million a quarter. Management argues it will "never pay that amount," but it remains a real, interest-bearing liability that the prospective fix doesn't touch.

The other levers. Uplisting: already done — TRLV is the proof-of-concept, and Russell 2000 inclusion is flagged for ~spring 2027. Interstate commerce: no movement; Trulieve's low-cost Florida cultivation would be an asset if it ever comes, but that's a future-state thesis. Consolidation: with $256 million cash and the cleanest medical-only currency in the group, Trulieve is positioned as a buyer, and management said valuations make it "inquisitive." Broad rescheduling: the June 29 DEA hearing on moving all marijuana to Schedule III is the prize — because 280E keys off the drug's schedule, a broad order would lift the tax for adult-use too (even without legalizing recreational sales), re-rating the whole sector's earnings.

5. Valuation — What It's Worth If It's a Normal Business

Today Trulieve trades at roughly $9.13, a ~$1.9 billion market cap, ~$2.0 billion enterprise value — about 4.7x adjusted EBITDA and 1.7x revenue. Consumer-staples and health-and-wellness peers that also generate ~60% gross margins and durable cash flow (Constellation Brands ~12x EV/EBITDA, the broader CPG set ~10–14x) trade at two to three times that multiple. The gap is the 280E/Schedule I discount. Two lenses on what closes it:

Scenario DCF (unlevered FCF, stated assumptions). Base case — 280E persists on adult-use, only medical relief, ~3% growth, 14% WACC (elevated for a name with a Schedule-I history), 2.5% terminal: ~$8–10/share. Broad-rescheduling case — 280E removed sector-wide, ~25% cash tax, ~4% growth, 12.5–14% WACC: ~$11–14/share. The base case lands right around today's price, which tells you the market is pricing medical relief but not broad rescheduling.
Cross-sector re-rating on $427M adjusted EBITDA. At 8x (a modest premium to today's 5x) implied equity is ~$16/share; at 10x, ~$20; at 12x — the Constellation multiple — ~$24. This is the "if it traded like the normal, cash-generative CPG business it resembles" lens.

Put together, the implied-value band runs from roughly $8–10 (DCF base, ≈ today) to the low-$20s (full CPG re-rating), with a broad-rescheduling DCF around the low-to-mid teens. At $9.13, the market is paying for medical 280E relief and essentially nothing else — not broad rescheduling, not a CPG re-rating, not the back-tax liability ever being resolved favorably. This is implied value under explicit assumptions, not a price target and not advice. (For context on the coverage vacuum closing: sell-side analysts — newly able to publish on an NYSE name — have started initiating, with a cluster of targets in the high-teens to ~$21; we cite that only as evidence the gap is being noticed, not as our number.)

6. Risks and Open Questions

The bull case rests on policy that is real but contested. The partial Schedule III order is under a pending D.C. Circuit emergency stay (filed by prohibitionist groups and GOP-led states arguing the AG's treaty-authority shortcut was unlawful) — a stay or vacatur would pull the predicate out from under the medical 280E relief and the uplisting rationale, and could force Trulieve to reverse FY2026 tax positions. The June 29 DEA hearing on broad rescheduling is stacked entirely with opponents (seven anti-rescheduling parties invited, zero in favor), so the adult-use prize is far from assured. Florida adult-use is dead until at least 2028 after the state Supreme Court declined rehearing in March 2026 — a direct hit to Trulieve's single largest market. The $630 million 280E back-tax reserve is a genuine liability the IRS is actively litigating, not a refund waiting to happen. Trulieve is one of nine MSOs named in the Ohio Attorney General's February 2026 antitrust "cannabis cartel" suit. State price compression continues. And ~47% of assets are goodwill and intangibles, leaving impairment exposure if Florida stays weak. Each of these is concrete, dated, and unresolved — present them as scenarios, not footnotes.

7. The Bottom Line

Trulieve is the cleanest expression of the cannabis catalyst trade: a 60%-gross-margin, free-cash-generative market leader whose only problem is a tax code, and which has already proven it can restructure into a medical-only entity to capture the fix and clear the NYSE. Today the business earns ~$118 million of normalized, 280E-relieved earning power and trades at ~5x EBITDA and a ~12% free-cash-flow yield — pricing in medical relief but pricing out broad rescheduling, a CPG re-rating, and any favorable resolution of the back-tax bill. The framework from here is simple to watch: the D.C. Circuit stay ruling and the June 29 DEA hearing set whether the catalyst broadens or stalls; Florida pricing and the quarterly effective tax rate show whether the operating reset and the 280E relief are sticking; and the $696 million UTP reserve is the overhang to keep one eye on. The data says this is a real, profitable business hiding behind a punitive tax rate. What it's worth depends on how far the policy goes — and that, not the operations, is the variable. You decide.

Built with RoboSystems — structured SEC/XBRL filing data for every public company: https://robosystems.ai. New customers get 50% off your first month with code CANNABIS50.